Becton Dickinson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Becton Dickinson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BDX

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. 

CEO
Thomas E. Polen
CEOThomas E. Polen
Employees
72,000
Employees72,000
Headquarters
Franklin Lakes, New Jersey
HeadquartersFranklin Lakes, New Jersey
Founded
1897
Founded1897
Employees
72,000
Employees72,000

BDX Key Statistics

Market cap
57.47B
Market cap57.47B
Price-Earnings ratio
34.70
Price-Earnings ratio34.70
Dividend yield
2.07%
Dividend yield2.07%
Average volume
1.78M
Average volume1.78M
High today
$205.52
High today$205.52
Low today
$195.63
Low today$195.63
Open price
$205.51
Open price$205.51
Volume
3.00M
Volume3.00M
52 Week high
$251.99
52 Week high$251.99
52 Week low
$162.29
52 Week low$162.29

Stock Snapshot

The current Becton Dickinson(BDX) stock price is $201.79, with a market capitalization of 57.47B. The stock trades at a price-to-earnings (P/E) ratio of 34.70 and offers a dividend yield of 2.1%.

On 2026-01-24, Becton Dickinson(BDX) stock moved within a range of $195.63 to $205.52. With shares now at $201.79, the stock is trading +3.1% above its intraday low and -1.8% below the session's peak.

Trading volume for Becton Dickinson(BDX) stock has reached 3M, versus its average volume of 1.78M.

The stock's 52-week range extends from a low of $162.29 to a high of $251.99.

The stock's 52-week range extends from a low of $162.29 to a high of $251.99.

BDX News

Simply Wall St 8h
Assessing Becton Dickinson Valuation After New Biologics Syringe And AI Research Platform Launches

Becton Dickinson (BDX) has been in focus after two product announcements: a 5.5 mL Neopak XtraFlow syringe for large volume biologics, and the global launch of...

Assessing Becton Dickinson Valuation After New Biologics Syringe And AI Research Platform Launches
Nasdaq 1d
BDX Stock Slides 2% After Company Unveils AI-Powered Research Platform

(RTTNews) - Becton, Dickinson and Company (BDX) shares fell 2.46% to $200.98, down $5.06, after the company announced the launch of new AI-powered tools to adva...

BDX Stock Slides 2% After Company Unveils AI-Powered Research Platform
Simply Wall St 3d
Becton Dickinson FDA Win Adds Breast Biopsy Growth And Valuation Interest

Becton Dickinson (NYSE:BDX) received FDA clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System. The clearance adds a new multi modality bre...

Becton Dickinson FDA Win Adds Breast Biopsy Growth And Valuation Interest

Analyst ratings

69%

of 16 ratings
Buy
31.3%
Hold
68.8%
Sell
0%

More BDX News

TipRanks 4d
Becton Dickinson, Ypsomed expand partnership

Becton Dickinson (BDX) and Ypsomed are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Sy...

People also own

Based on the portfolios of people who own BDX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.